
Opinion|Videos|January 29, 2026
Hope on the Horizon: The Future of GCA Treatment
Advertisement
Episodes in this series

This video covers the following questions:
- Let’s close this series by discussing the future of GCA management. How can clinicians continue to close the gaps in diagnosis and management, and what do you hope is on the horizon for GCA treatment?
Thank you again to our panel, and thanks to our audience for watching. We hope you found this HPC Live Peer Exchange to be useful and informative.
Advertisement
Related to this article

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.
Advertisement
Advertisement
Trending on HCPLive
1
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
2
FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
5

